Outsourcing facilities are only allowed to compound drugs with five bulk substances — diphenylcyclopropenone, glycolic acid, quinacrine hydrochloride, squaric acid dibutyl ester and trichloroacetic acid — for specific uses, such as topical or oral use.
The FDA has evaluated and blocked 20 other solutions from joining the list, according to documents.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
